Schellhammer PF - Search Results

1

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.

Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Small EJ, Heath EI, Tutrone RF, Schellhammer PF, Harmon M, Chang NN, Sheikh NA, Brown B, Freedland SJ, Higano CS. Sartor O, et al. Among authors: schellhammer pf. Prostate Cancer Prostatic Dis. 2020 Sep;23(3):517-526. doi: 10.1038/s41391-020-0213-7. Epub 2020 Feb 28. Prostate Cancer Prostatic Dis. 2020. PMID: 32111923 Free PMC article.

2

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW. Higano CS, et al. Among authors: schellhammer pf. Cancer. 2009 Aug 15;115(16):3670-9. doi: 10.1002/cncr.24429. Cancer. 2009. PMID: 19536890 Free article. Clinical Trial.

3

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Schellhammer PF, et al. Urology. 2013 Jun;81(6):1297-302. doi: 10.1016/j.urology.2013.01.061. Epub 2013 Apr 9. Urology. 2013. PMID: 23582482 Clinical Trial.

4

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Small EJ, et al. Among authors: schellhammer pf. J Clin Oncol. 2006 Jul 1;24(19):3089-94. doi: 10.1200/JCO.2005.04.5252. J Clin Oncol. 2006. PMID: 16809734 Clinical Trial.

5

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. Kantoff PW, et al. Among authors: schellhammer pf. N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294. N Engl J Med. 2010. PMID: 20818862 Free article. Clinical Trial.

6

Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer.

Shore ND, Schellhammer PF, Tutrone RF, Mariados NF, Harrelson SS. Shore ND, et al. Among authors: schellhammer pf. Clin Genitourin Cancer. 2020 Oct;18(5):416-422. doi: 10.1016/j.clgc.2020.02.015. Epub 2020 Apr 18. Clin Genitourin Cancer. 2020. PMID: 32475774 Clinical Trial.

7

The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer.

Sartor O, McLeod DG, Halabi S, Schellhammer PF, Scardino PT, D'Amico AV, Bennett C, Wei JT; COMPARE Registry Steering Committee. Sartor O, et al. Among authors: schellhammer pf. Urology. 2010 Mar;75(3):623-9. doi: 10.1016/j.urology.2009.04.059. Epub 2009 Jul 8. Urology. 2010. PMID: 19589569

8

Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.

McLeod DG, Schellhammer PF, Vogelzang NJ, Soloway MS, Sharifi R, Block NL, Venner PM, Patterson AL, Sarosdy MF, Kelley RP, Kolvenbag GJ. McLeod DG, et al. Among authors: schellhammer pf. Prostate. 1999 Sep 1;40(4):218-24. doi: 10.1002/(sici)1097-0045(19990901)40:4<218::aid-pros2>3.0.co;2-6. Prostate. 1999. PMID: 10420149 Clinical Trial.

9

Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.

Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF. Kantoff PW, et al. Among authors: schellhammer pf. J Natl Cancer Inst. 2012 Jul 18;104(14):1107-9; author reply 1109-12. doi: 10.1093/jnci/djs279. J Natl Cancer Inst. 2012. PMID: 22825556 No abstract available.

10

Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.

Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F. Crawford ED, et al. Among authors: schellhammer pf. J Urol. 2018 Nov;200(5):956-966. doi: 10.1016/j.juro.2018.04.083. Epub 2018 May 3. J Urol. 2018. PMID: 29730201 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

325 results

Search Page